ARALEN HYDROCHLORIDE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Oct 1949
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARALEN HYDROCHLORIDE is an injectable small-molecule antimalarial agent approved in 1949 by Sanofi. The exact mechanism of action and full indication set are not specified in available data, but historical context suggests use in malaria and related parasitic infections. This is a legacy product with decades of clinical use.
LOE Approaching
This legacy product is approaching loss of exclusivity with minimal competitive pressure signals (30/100), indicating a contracted commercial team focused on defending market share in niche indications.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ARALEN HYDROCHLORIDE offers limited career growth opportunities given its LOE-approaching status and zero linked job openings in the dataset. This role suits professionals focused on lifecycle management expertise, international markets, or legacy product optimization rather than career acceleration.
Brand ManagerField Sales Representative
Worked on ARALEN HYDROCHLORIDE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.